Study on the clinical effect and the influence to coagulation factor of carboprost tromethamine on the treatment of the patients with postpartum hemorrhage / 中国生化药物杂志

ABSTRACT

Objective To investigate the clinical effect and the influence to coagulation factor of carboprost tromethamine on the treatment of the patients with postpartum hemorrhage. Methods 60 pregnant women with placenta previa complicated with postpartum hemorrhage from May 2016 to March 2017 were randomly divided into the control group (n=30) and the observation group (n=30). The control group were given oxytocin, the observation group were received carboprost tromethamine. Fibrinogen (FIB), prothrombin time (APTT), prothrombin time (PT) and platelet count before and after surgery in the two groups were analyzed by CA7000 automatic blood analyzer. The effect and coagulation indexes in the two groups were compared. Results The clinical curative rate in the observation group was 96.67% and 93.33% in the control group, the differences had no statistically significant. The amount of hemorrhage in postpartum 2h and 24h and the hemoglobin in postpartum 24h in the observation group were less than those in the control group (P<0.05); There was no significant difference about coagulation indexes between the 2 groups before treatment;The platelet count, PT and APTT levels in the observation group were lower than those in the control group, and the level of FIB was higher than that in the control group (P<0.05); The incidence of adverse reaction was 6.67% in the observation group and 10% in the control group, the difference was not statistically significant. Conclusion Choosing carboprost tromethamine to treat placenta prevail complicated with postpartum hemorrhage has a good curative effect, which is helpful to reduce the amount of postpartum hemorrhage and improve the coagulation indexes, so it is worth popularizing